You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Combining faster detection with ID: a new paradigm for mycobacterial culture
SBC: Specific Diagnostics, Inc. Topic: NIAIDProject Summary Abstract TuberculosisTBis one of the leading causes of morbidity and mortality from infectious disease worldwide with an estimatedmillion cases of active TB andmillion deaths from the disease annuallyDespite emerging new technologiesculture remains the gold standard in TB diagnosis and therapeutic monitoringInthe World Health OrganizationWHOrecommended the use of a liquid culturing ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of an H2O2-inactivated chikungunya virus vaccine
SBC: NAJIT TECHNOLOGIES INC Topic: RChikungunya virusCHIKVis an alphavirus that has gained significant attention due to its ability to cause large epidemics among susceptible populations and to be spread beyond endemic countries by international travelersAmong a population of approximatelyon the French island of La Reunionpeople were infected and overCHIKV related fatalities occurred during theoutbreakLikewisean estimatedmillion peo ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
A Phase III Trial to Validate HP 129Xe MRI as a Functional Pulmonary Biomarker in Pediatric Lung Disease
SBC: POLAREAN, INC. Topic: NHLBIPROJECT SUMMARYABSTRACT Chronic respiratory diseasessuch as COPDasthmaand cystic fibrosisCFare therd leading cause of death in the USwith costs exceeding $B yearA major obstacle to evaluate therapies for these diseases is that currently available tools to assess lung function are either insensitive to early disease or unsuitable for longitudinal useThough ubiquitouspulmonary function testing via s ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Discovering a Disease Modifying Therapeutic to Treat Huntington's Disease
SBC: CHAPERONE THERAPEUTICS, INC. Topic: NIAProtein misfolding and aggregationleading to chronic inflammationsynaptic dysfunction and neuronal death are common hallmarks of neurodegenerative diseases including Alzheimer s diseaseADand Huntington s diseaseHDWhile overmillion Americans suffer from ADand oversuffer from HDcurrent therapies target symptoms but not the underlying pathophysiology of protein misfoldingaggregation and its downstrea ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
A Topical Non-steroidal Anti-inflammatory for Atopic Dermatitis
SBC: SIGNUM BIOSCIENCES, INC. Topic: NIAIDSUMMARY Atopic dermatitis is a chronic dermatological condition afflicting mostly infants and young childrenCurrent treatments are associated with a wide range of side effects therefore development of novel therapeutic agents that are efficacious and have an improved safety profile is neededAlthough disease etiology has yet to be fully understoodskin inflammation is known to be critically involved ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Marketing Strategic Plan and Distribution Logistics for Sanaria PfSPZ Vaccine against Malaria.
SBC: SANARIA INC. Topic: NIAIDABSTRACT The development of Sanaria s Plasmodium falciparumPfsporozoiteSPZbased vaccines is receiving overwhelming global support after the publication inin Science of clinical data showingprotection against controlled human malaria infectionCHMIfollowing intravenous administration ofdoses of SanariaPfSPZ Vaccinecomposed of purifiedasepticradiation attenuatedcryopreserved PfSPZ meeting all regulat ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids
SBC: ELYSIUM THERAPEUTICS, INC. Topic: NIDAProject SummaryAbstractAddiction is a diseaseAccording to the National Institute on Drug Abuseaddiction can be hereditaryand canbetriggeredbyenvironmentalconditionsandbehaviorOnekeyenvironmentalfactorinvolvesthereadyaccess to unused prescription opioids by potential abusersespecially teensElysium has discovered a novel molecular deactivationXpiRxorexpiring pilltechnology that is designedto effecti ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of methionyl-tRNA synthetase inhibitors for Gram positive bacterial infections
SBC: TSRL, INC. Topic: NIAIDThe objective of this research is to develop a novel antibiotic targeting Gram positive bacteriawith an initial clinical indication of acute bacterial skin and skin structure infectionsABSSSIThe research will address the urgent problem of antibiotic resistant bacteria that are spreading around the worldThe new antibiotic is being designed to inhibit a novel targetthe bacterial methionyltRNA synthe ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Immune Deficient Mosquitoes for Improved Malaria Sporozoite Vaccine Manufacture
SBC: SANARIA INC. Topic: NIAIDAbstract An ideal tool for eliminating Plasmodium falciparumPfthe causative agent ofof all malaria deathswould be a highly effective vaccine that prevents blood stage infection and thereby prevents both disease and transmissionSanaria has developed two effective vaccines that are phaseclinical trialsPf sporozoiteSPZvaccine that prevents Pf blood stage infection in andgtof recipients and PfSPZ Chal ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
PANDAA for rapid genotyping of HIV-1 infected patients failing protease inhibitor ART in resource-limited settings
SBC: ALDATU BIOSCIENCES INC Topic: RTheWHO guidelines recommend anti retroviral therapyARTfor all HIV infected peopleand massive efforts to expand ART access will result in andgtM adults and andgtM children on ART byat a cost of almost US$BConsequentlythe number of patients prescribed alternativeprotease inhibitorPIbased ART following failure of first line regimens will also increaseStudies of patients on PI based ART in resource li ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health